(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 December 2018 (13.12.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/224573 A8

(51) International Patent Classification:
A61K 39/12 (2006.01) *A61K 39/00* (2006.01)

(21) International Application Number:
PCT/EP2018/064943

(22) International Filing Date:
06 June 2018 (06.06.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
17305676.3 07 June 2017 (07.06.2017) EP

(71) Applicants: **INSTITUT PASTEUR** [FR/FR]; 25-28, rue du Docteur Roux, 75724 PARIS CEDEX 15 (FR). **CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE** [FR/FR]; 3, rue Michel-Ange, 75794 PARIS CEDEX 16 (FR).

(72) Inventors: **TANGY, Frédéric**; 60, rue du Garde Chasse, 93260 LES LILAS (FR). **SIMON-LORIERE, Etienne**; 69, avenue de Clichy, 75017 PARIS (FR).

(74) Agent: **ERNEST GUTMANN - YVES PLASSERAUD SAS - DESAIX ANNE, ALMOND MARTIN CAROL, DERAMBURE CHRISTIAN, JOLLY CHRISTOPHE, LEJEUNE ANNE, PERNOT PIERRE, PICHAT THIERRY, ROBERT MATHIAS, SELLIN CAROLE**; 3, rue Auber, 75009 PARIS (FR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))*
— *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:
25 July 2019 (25.07.2019)

(15) Information about Correction:
see Notice of 25 July 2019 (25.07.2019)

(54) Title: RECOMBINANT MEASLES VIRUS EXPRESSING ZIKA VIRUS PROTEINS AND THEIR APPLICATIONS

(57) Abstract: The present invention relates to recombinant measles virus expressing Zika virus proteins and their applications, in particular in inducing preventive protection against Zika virus. The present invention is directed to recombinant measles virus (MV) expressing at least (i) the precursor of membrane (prM) protein of a Zika virus (ZIKV), and the envelope (E) protein of a ZIKV or a truncated version thereof, or (ii) the E protein of a ZIKVor a truncated version thereof, and concerns recombinant infectious particles of said MV-ZIKV able to replicate in a host after an administration, and also Virus Like Particles (VLPs) that contain these ZIKV proteins at their surface. The present invention provides means, in particular nucleic acids, vectors, cells and rescue systems to produce these recombinant infectious particles and VLPs. The present invention also relates to the use of these recombinant infectious particles and/or VLPs, in particular under the form of a composition, more particularly in a vaccine formulation, for the prevention of an infection by ZIKV or for the preventive protection against clinical outcomes of ZIKV infection.

WO 2018/224573 A8